Universal mRNA Flu Vaccine PanVax Approved by FDA: One Shot Covers All Known Influenza Strains

Universal mRNA Flu Vaccine PanVax Approved by FDA

On September 17, 2030, the U.S. FDA approved PanVax, a universal mRNA influenza vaccine developed by Moderna. Unlike traditional flu vaccines that require annual formula updates based on circulating strains, PanVax achieves one-shot immunity covering all known influenza A and B strains by targeting conserved epitopes of the influenza virus that rarely mutate.

The fundamental reason flu vaccines require annual updates is that traditional vaccines target the virus's surface hemagglutinin (HA) protein, whose antigenic regions undergo drift every year. PanVax's breakthrough lies in shifting the target to the virus's internal matrix protein M1 and nucleoprotein NP — both highly conserved across all influenza strains (over 90% similarity) because they carry core structural functions of the virus, leaving extremely limited room for mutation.

Moderna Chief Medical Officer Stephen Hoge explained at the press conference: "Traditional vaccines are like sending the immune system a new suspect photo every year, whereas PanVax teaches the immune system to recognize the common features of all suspects — walking posture, height and build — things that don't change just because they switched clothes."

In a Phase 3 clinical trial involving 45,000 participants, PanVax showed 78% protective efficacy against all influenza A strains and 82% against influenza B. In comparison, the 2029-2030 traditional flu vaccine achieved 65% efficacy against matched strains and only 23% against unmatched strains. More importantly, PanVax's protection is expected to last three to five years, eliminating the need for annual vaccination.

The FDA specifically noted in its approval statement that PanVax's mRNA platform uses the same technology pathway as COVID-19 vaccines, meaning existing large-scale manufacturing capacity can be directly reused. Moderna plans to produce 500 million doses of PanVax before the 2031 flu season.

PanVax is priced at $85 per dose, higher than the $30 to $50 for traditional flu vaccines, but considering no annual vaccination is needed, the total three-year cost is actually lower. The U.S. Centers for Disease Control and Prevention (CDC) has recommended incorporating PanVax into the adult routine immunization schedule.

Notably, PanVax's protective efficacy against avian influenza H5N1 subtype is 68%, lower than seasonal flu strains. Moderna says it is developing a booster version specifically targeting H5N1.